Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Schizophrenia is a profoundly debilitating disease that represents not only an individual, but a societal problem. Once characterized solely by the hyperactivity of the dopaminergic system, therapies directed to dampen dopaminergic neurotransmission were developed. However, these drugs do not address the significant impairments in cognition and the negative symptoms of the disease, and it is now apparent that disequilibrium of many neurotransmitter systems is involved. Despite enormous efforts, minimal progress has been made toward the development of safer, more effective therapies to date. AREAS COVERED: The high preponderance of smoking in schizophrenics suggests that nicotine may provide symptomatic improvement, which has led to investigation for selective molecules targeted to individual nicotinic receptor (nAChR) subtypes. Of special interest is activation of the homomeric α7nAChR, which is widely distributed in the brain and has been implicated in the pathophysiology of schizophrenia through numerous approaches. EXPERT OPINION: Preclinical and clinical data suggest that neuronal α7nAChRs play an important role in cognitive functions. Moreover, some, but not all, early clinical trials conducted with α7nAChR agonists show cognitive benefits in schizophrenics. These encouraging results suggest that development of compounds targeting α7nAChRs will represent a valuable tool to mitigate symptoms associated with schizophrenia, and open new strategies for better pharmacological treatment of these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999 · cited 1×
“Impairments in cognition are more closely related to the daily functioning of the individual and are a better predictor of functional outcome than positive symptoms [6].”
BackgroundSchizophrenia as a Complex Trait: Evidence From a Meta-analysis of Twin Studies
Sullivan, P. F., Kendler, K. S., & Neale, M. C. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1187 · Cited by 2,356 · cited 1×
“Whereas many genetic studies have been conducted in attempt to pinpoint the cause of the disease, it has become clear that schizophrenia is a complex trait that cannot be associated with the alteration of a single gene [8].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Genome-wide association study identifies five new schizophrenia loci
The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (2011) · Nature Genetics · doi:10.1038/ng.940 · Cited by 1,919
Large recurrent microdeletions associated with schizophrenia.
GROUP, Stefansson, H., Rujescu, D., Cichon, S., Pietiläinen, O. P. H., Ingason, A., Steinberg, S., Fossdal, R., Sigurdsson, E., Sigmundsson, T., et al. (2008) · Nature · doi:10.1038/nature07229 · Cited by 1,745 · cited 1×
“3 [109] that is in close vicinity with a gene deletion that was recently reported in a schizophrenic study [110,111].”
BackgroundMammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
City living and urban upbringing affect neural social stress processing in humans
Lederbogen, F., Kirsch, P., Haddad, L., Streit, F., Tost, H., Schuch, P., Wüst, S., Pruessner, J. C., Rietschel, M., Deuschle, M., et al. (2011) · Nature · doi:10.1038/nature10190 · Cited by 1,584 · cited 1×
“The large number of genetic variants proposed to be linked to schizophrenia brought certain authors to the conclusion that genome variations could be considered as predisposing factors but that additional causes, such as environment, are strongly influential in the physiopathology of the disease [12,13].”
BackgroundRare chromosomal deletions and duplications increase risk of schizophrenia
The International Schizophrenia Consortium (2008) · Nature · doi:10.1038/nature07239 · Cited by 1,475
Modelling schizophrenia using human induced pluripotent stem cells
Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., et al. (2011) · Nature · doi:10.1038/nature09915 · Cited by 1,375 · cited 1×
“A first data set obtained from neurons derived from human iPSCs derived from schizophrenic patients offered a first window for in vitro exploration of the disease [137].”
BackgroundGrouping of brain rhythms in corticothalamic systems
Steriade, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.029 · Cited by 1,296
Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Self-citationGenetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177
Steinlein, O. K., Mulley, J. C., Propping, P., Wallace, R. H., Phillips, H. A., Sutherland, G. R., Scheffer, I. E., & Berkovic, S. F. (1995) · Nature Genetics · doi:10.1038/ng1095-201 · Cited by 1,134
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979 · cited 1×
“, stimulant) of smoking [22,23].”
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 1×
“Additional evidence supporting a possible role of a7 in schizophrenia was provided by the observation of a reduction in a-bungarotoxin labeling in postmortem characterization of brain tissue from schizophrenic patients [114].”
BackgroundHuman memory strength is predicted by theta-frequency phase-locking of single neurons
Rutishauser, U., Ross, I. B., Mamelak, A. N., & Schuman, E. M. (2010) · Nature · doi:10.1038/nature08860 · Cited by 622
Behavioral and Intellectual Markers for Schizophrenia in Apparently Healthy Male Adolescents
Davidson, M., Reichenberg, A., Rabinowitz, J., Weiser, M., Kaplan, Z., & Mark, M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1328 · Cited by 582
Structural and functional diversity of native brain neuronal nicotinic receptors
Gotti, C., Clementi, F., Fornari, A., Gaimarri, A., Guiducci, S., Manfredi, I., Moretti, M., Pedrazzi, P., Pucci, L., & Zoli, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.024 · Cited by 469
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · cited 1×
“1 Clinical The early observation that the a7 partial agonist DMXB-A (also known as GTS-21) improved the cognitive performance in the Repeatable Battery for the Assessment of Neuropsychological Status in a cohort of non-smoking schizophrenic patients provided a remarkable proof of concept concerning the role of nicotin…”
BackgroundLynx1, a Cholinergic Brake, Limits Plasticity in Adult Visual Cortex
Morishita, H., Miwa, J. M., Heintz, N., & Hensch, T. K. (2010) · Science · doi:10.1126/science.1195320 · Cited by 365 · cited 1×
“Additional complexity including modulation by accessory proteins and endogenous allosteric modulators such as SLURP-1 or Lynx-1 must also taken into account [95-99].”
BackgroundIncreased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies
Perry, D. C., Dávila-Garcı́a, M. I., Stockmeier, C. A., & Kellar, K. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38304-1 · Cited by 362
Chronic Exposure to Nicotine Upregulates the Human α4β2 Nicotinic Acetylcholine Receptor Function
Buisson, B., & Bertrand, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-06-01819.2001 · Cited by 361
Self-citationGovind, A. P., Vezina, P., & Green, W. N. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.011 · Cited by 338
Chimienti, F. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg320 · Cited by 247 · cited 1×
“Additional complexity including modulation by accessory proteins and endogenous allosteric modulators such as SLURP-1 or Lynx-1 must also taken into account [95-99].”
BackgroundFifty years chlorpromazine: a historical perspective
Ban, T. A. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a922 · Cited by 227
Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses
Miwa, J. M., Freedman, R., & Lester, H. A. (2011) · Neuron · doi:10.1016/j.neuron.2011.03.014 · Cited by 205 · cited 1×
“Additional complexity including modulation by accessory proteins and endogenous allosteric modulators such as SLURP-1 or Lynx-1 must also taken into account [95-99].”
BackgroundTribollet, E., Bertrand, D., Marguerat, A., & Raggenbass, M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.09.028 · Cited by 199 · cited 1×
“Hence, in absence of specific antibodies allowing precise morphological studies, results remain limited essentially relying on high affinity ligands such as epibatidine and a-bungarotoxin [39-41].”
BackgroundSelf-citationNicotinic receptors in human brain: topography and pathology
Court, J. A., Martin-Ruiz, C., Graham, A., & Perry, E. (2000) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(00)00110-1 · Cited by 180
Othman, A. A., Lenz, R. A., Zhang, J., Li, J., Awni, W. M., & Dutta, S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010370460 · Cited by 24
Cited by
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Corradi, J., & Bouzat, C. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104240 · Cited by 167
“…emerging drug target; the participation of a7 in pathologic conditions and the therapeutic potential of a7 ligands has been well documented (see for example Taly and Changeux, 2008; Wallace and Porter, 2011; Lendvai et al., 2013; Wallace and Bertrand, 2013; Uteshev, 2014; Dineley et al., 2015).”
BackgroundImportance of the nicotinic acetylcholine receptor system in the prefrontal cortex
Wallace, T. L., & Bertrand, D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.001 · Cited by 133
Self-citationLee, C.-H., & Hung, S.-Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010031 · Cited by 50
“Preclinical and clinical data suggest that α7nAChR plays an important role in cognitive functions of schizophrenia [83].”
BackgroundStoiljkovic, M., Leventhal, L., Chen, A., Chen, T., Driscoll, R., Flood, D., Hodgdon, H., Hurst, R., Nagy, D., Piser, T., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.006 · Cited by 29
Self-citation
Metadata
- Authors
- Wallace, T. L., & Bertrand, D.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2012-12-11
- Volume
- 17
- Issue
- 2
- Pages
- 139-155
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2058751224
- Cited by
- 72
- References
- 30
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.